Voyager Therapeutics, Inc. (VYGR): Capital Expenditures
$2.60M
Year ended 2025-12-31
$847.0K
Trailing 12 months to 2026-06-30
+1.4%
3-year compound annual growth
-26.5%
5-year compound annual growth
+9.7%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.60M | -26.3% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $3.52M | +8.1% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $3.26M | +30.7% | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | $2.49M | +54.8% | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | $1.61M | -86.7% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $12.10M | +56.7% | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $7.72M | +79.3% | 2022-03-08, From 2019-01-01 |
| 2018-12-31 | $4.30M | +8.0% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $3.98M | -20.8% | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | $5.03M | +388.3% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $1.03M | -65.5% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $2.99M | n/a | 2017-03-15, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $607.0K | +237.2% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $1.64M | +27.8% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $155.0K | +10.7% |
Compare VYGR, EDIT, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗